Metabolomic studies of NASH and NAFLD
Nonalcoholic fatty liver disease (NAFLD), a disease in which fat builds up in the liver, affects approximately 25% of the global adult population and is the most common chronic liver disease in the world. NAFLD includes a range of diseases, from the most basic steatosis, to nonalcoholic steatohepatitis (NASH), cirrhosis, to the more advanced hepatocellular carcinoma (hepatocellular carcinoma). As the disease progresses, hepatic lipid accumulation is accompanied by excessive inflammation and oxidative stress, and hepatic fibrosis, a clinical major risk predictor for NASH disease staging, can eventually be detected.
